Skip to main content
Top
Published in: Infection 6/2019

Open Access 01-12-2019 | Rifampicin | Case Report

Report on an unusual case of leprosy from Germany: just an exception of the rule?

Published in: Infection | Issue 6/2019

Login to get access

Abstract

Case presentation

We report on a German leprosy patient originating from Pakistan who had a relapse more than 5 years after completion of multi-drug therapy (MDT) of his first episode of multibacillary (MB) leprosy. State-of-the-art laboratory techniques (histopathology, PGL-I serology, microscopy and DNA/RNA qPCR) were applied for laboratory confirmation and monitoring of treatment outcome. Serology indicated the relapse long before the presence of unambiguous clinical signs. At the time of diagnosis of the relapse the patient had a remarkably high bacterial load suggesting increased risk for a second relapse. Furthermore, unexpectedly prolonged excretion of viable bacilli through the upper respiratory tract for more than 3 months after onset of MDT was shown. Therefore, MDT was administered for 2 years.

Discussion and conclusions

The clinical course of the patient, as well as the prolonged excretion of viable bacilli, underlines the usefulness of laboratory assessment. Laboratory tools including up-to-date molecular assays facilitate rapid diagnosis, timely MDT, identification of individuals excreting viable bacilli and patients at risk for relapses, monitoring of treatment outcome and respective adaptation of treatment where appropriate.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rodrigues LC, Lockwood DNJ. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11:464–70.CrossRef Rodrigues LC, Lockwood DNJ. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11:464–70.CrossRef
3.
go back to reference WHO. WHO Expert Committee on Leprosy—Eighth report, vol. 68. Geneva: World Health Organ Tech Rep Ser; 2012. pp. 1–61. WHO. WHO Expert Committee on Leprosy—Eighth report, vol. 68. Geneva: World Health Organ Tech Rep Ser; 2012. pp. 1–61.
4.
go back to reference Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect. 2015;45:383–93.CrossRef Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect. 2015;45:383–93.CrossRef
5.
go back to reference Araujo S, Freitas LO, Goulart LR, Goulart IMB. Molecular evidence for the aerial route of infection of Mycobacterium leprae and the role of asymptomatic carriers in the persistence of leprosy. Clin Infect Dis. 2016;63:1412–20.CrossRef Araujo S, Freitas LO, Goulart LR, Goulart IMB. Molecular evidence for the aerial route of infection of Mycobacterium leprae and the role of asymptomatic carriers in the persistence of leprosy. Clin Infect Dis. 2016;63:1412–20.CrossRef
6.
go back to reference Guidelines for the diagnosis. Treatment and prevention of leprosy. New Delhi: World Health Organization, Regional Office for South-East Asia; 2018. Guidelines for the diagnosis. Treatment and prevention of leprosy. New Delhi: World Health Organization, Regional Office for South-East Asia; 2018.
7.
go back to reference Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, Ganapati R. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; Part 3—study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT 1 steroids vs MDT alone, assessed at 6 months post—release from 12 months MDT. Lepr Rev. 2010;81:41–58.PubMed Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, Ganapati R. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; Part 3—study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT 1 steroids vs MDT alone, assessed at 6 months post—release from 12 months MDT. Lepr Rev. 2010;81:41–58.PubMed
8.
go back to reference Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis. 2004;72:493–500.CrossRef Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis. 2004;72:493–500.CrossRef
9.
go back to reference Shetty VP, Wakade AV, Ghate SD, Pai VV. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai. Lepr Rev. 2011;82:235–43.PubMed Shetty VP, Wakade AV, Ghate SD, Pai VV. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai. Lepr Rev. 2011;82:235–43.PubMed
10.
go back to reference Massone C, Brunasso AM, Noto S, Campbell TM, Clapasson A, Nunzi E. Imported leprosy in Italy. J Eur Acad Dermatol Venereol. 2012;26:999–1006.CrossRef Massone C, Brunasso AM, Noto S, Campbell TM, Clapasson A, Nunzi E. Imported leprosy in Italy. J Eur Acad Dermatol Venereol. 2012;26:999–1006.CrossRef
11.
go back to reference Ramos JM, Romero D, Belinchón I. Epidemiology of leprosy in Spain: the role of the international migration. PLoS Negl Trop Dis. 2016;10:e0004321.CrossRef Ramos JM, Romero D, Belinchón I. Epidemiology of leprosy in Spain: the role of the international migration. PLoS Negl Trop Dis. 2016;10:e0004321.CrossRef
13.
go back to reference Sticht Groh V, Alvarenga AE. Use of a different buffer system in the phenolic glycolipid-I ELISA. Int J Lepr. 1992;60:570–4. Sticht Groh V, Alvarenga AE. Use of a different buffer system in the phenolic glycolipid-I ELISA. Int J Lepr. 1992;60:570–4.
14.
go back to reference Beissner M, Wöstemeier A, Saar M, Badziklou K, Maman I, Amedifou C et al. Development of a combined RLEP/16S rRNA (RT) qPCR assay for the detection of viable M. leprae from Nasal Swab samples. BMC Infect Dis. 2019 (accepted Jul 2019). Beissner M, Wöstemeier A, Saar M, Badziklou K, Maman I, Amedifou C et al. Development of a combined RLEP/16S rRNA (RT) qPCR assay for the detection of viable M. leprae from Nasal Swab samples. BMC Infect Dis. 2019 (accepted Jul 2019).
15.
go back to reference Benjak A, Avanzi C, Sigh P, Loiseau C, Girma S, Busso P, et al. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae. Nat Commun. 2018;9:352–62.CrossRef Benjak A, Avanzi C, Sigh P, Loiseau C, Girma S, Busso P, et al. Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae. Nat Commun. 2018;9:352–62.CrossRef
16.
go back to reference Cambeau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clin Microbiol Infect. 2018;24:1305–10.CrossRef Cambeau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clin Microbiol Infect. 2018;24:1305–10.CrossRef
17.
go back to reference Mc Rae DH, Shepard CC. Relationship between the staining quality of Mycobacterium leprae and infectivity for Mice. Infect Immun. 1971;3:116–20. Mc Rae DH, Shepard CC. Relationship between the staining quality of Mycobacterium leprae and infectivity for Mice. Infect Immun. 1971;3:116–20.
18.
go back to reference Katoch CM, Katoch K, Ramu GM, Sharma VD, Datta AK, Shivannavar CT, Desikan KV. In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index and FDA-EB fluorescent staining in Mycobacterium leprae. Lepr Rev. 1988;59:137–43.PubMed Katoch CM, Katoch K, Ramu GM, Sharma VD, Datta AK, Shivannavar CT, Desikan KV. In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index and FDA-EB fluorescent staining in Mycobacterium leprae. Lepr Rev. 1988;59:137–43.PubMed
19.
go back to reference Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, Williams DL. Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J clin Microbiol. 2009;47:2124–30.CrossRef Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, Williams DL. Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J clin Microbiol. 2009;47:2124–30.CrossRef
20.
go back to reference Chin-A-Lien RAM, Faber WR, van Rens MM, Leiker DL, Naafs B, Klatser PR. Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Lepr Rev. 1992;63:21–7.PubMed Chin-A-Lien RAM, Faber WR, van Rens MM, Leiker DL, Naafs B, Klatser PR. Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Lepr Rev. 1992;63:21–7.PubMed
21.
go back to reference Shepard CC, McRae DH. Mycobacterium leprae in Mice: minimal infectious dose, relationship between staining quality and infectivity, and effect of cortisone. J Bacteriol. 1965;98:365–72. Shepard CC, McRae DH. Mycobacterium leprae in Mice: minimal infectious dose, relationship between staining quality and infectivity, and effect of cortisone. J Bacteriol. 1965;98:365–72.
22.
23.
go back to reference Ebenezer GJ, Daniel S, Norman G, Daniel E, Job CK. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months’ and 24 months’ multi-drug therapy? Indian J Lepr. 2004;76:199–206.PubMed Ebenezer GJ, Daniel S, Norman G, Daniel E, Job CK. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months’ and 24 months’ multi-drug therapy? Indian J Lepr. 2004;76:199–206.PubMed
Metadata
Title
Report on an unusual case of leprosy from Germany: just an exception of the rule?
Publication date
01-12-2019
Published in
Infection / Issue 6/2019
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01349-8

Other articles of this Issue 6/2019

Infection 6/2019 Go to the issue